re: Ann: Opthea Signs Cell Line Commercial Li...
They have plenty else going on as well
Could be time for that chart to turn upside down
For a biotech, pretty damn cheap -
$10 million cap $9 million in cash plus 2.2 million in listed shares
Control over 400 patents
Several therapeutic development partnering events expected during 2014.
Commercial partnerships already in place with:
- Eli Lilly: Developing IMC-3C5, a cancer treatment, with ImClone, a subsidiary of Eli Lilly (Eli Lilly makes Prozac, amongst other things)
- Merck Millipore
- Healthscope: Developed CupGuide, a molecular diagnostic for cancers of unknown primary origin, already on sale with orders and revenue to ramp up this year following oncologist education
- Perkin Elmer - Bio-rad - Ark Therapeutics
Ongoing royalty streams of $550k pa increasing to $1 million pa from this year
Collaborations with:
– Harvard – UCLA – CSIRO – Ludwig Institute of Cancer Research – University of Helsinki – Peter Maccallum Cancer Institute – Centre for Eye Research Australia
New licensing deal announced this morning with Selexis
Cancer inhibition technology/methodology I can actually understand:
Charts look just about ready for a reversal-
long term chart looks floored short term turning up with good OBV
Titus you must be a Peter Lynch fan as well!
CIR Price at posting:
23.5¢ Sentiment: Buy Disclosure: Held
